Analysis
What is the difference between 503A and 503B compounding?
Compare patient-specific 503A compounding with registered 503B outsourcing facilities, including prescriptions, oversight, manufacturing requirements and GLP-1 restrictions.
Claims are checked against the sources cited in this article. Nothing here is individualized medical advice. How we research
On this page
503A generally concerns compounding for identified individual patients by licensed pharmacists or physicians; 503B concerns registered outsourcing facilities with additional FDA oversight and manufacturing requirements. Neither category means the compounded drug is FDA-approved, and their rules cannot be used interchangeably.
Sources checked October 9, 2026. This guide explains the categories and how to read a pharmacy’s claim, not which product is medically appropriate or whether a particular facility complies with every requirement.
The quick comparison
| Question | 503A framework | 503B outsourcing facility |
|---|---|---|
| Patient-specific prescription? | Tied to identified individual patients; limited anticipatory compounding conditions also exist | Can compound with patient prescriptions or supply health care practitioners without first receiving one |
| Main day-to-day oversight? | Generally state pharmacy boards for state-licensed pharmacies; FDA also has authority | Primarily FDA, with risk-based inspections |
| Current good manufacturing practice requirements? | Exemption when all applicable 503A conditions are met | Apply to outsourcing facilities |
| FDA facility registration as an outsourcing facility? | Not implied by operating under 503A | Registration is part of the category |
| FDA-approved compounded product? | No | No |
FDA describes these differences in its compounding questions and answers and 503A guidance. The table is an orientation, not the complete list of statutory conditions.
What “503A” means in practice
The 503A framework is centered on identified patients and prescriptions. It applies to qualifying compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician. FDA’s guidance also describes limited compounding before receipt of a prescription based on an established prescription history; that is not permission for unrestricted bulk supply. FDA’s 503A framework guidance
A consumer encountering the term should still ask which pharmacy is involved. “Our pharmacy is 503A” is a category claim, not the pharmacy’s name, address or licensing record. Ask separately who prepares the prescription, who dispenses it and how to contact the pharmacist about its labeling.
The category also does not settle every product-specific restriction. A pharmacy may be licensed and still need to satisfy ingredient, prescription and copying conditions for a particular compounded preparation. Listing the framework is useful information, but it is not a complete explanation of that preparation’s legal basis.
What “503B” means in practice
Outsourcing facilities are a distinct category created by the Drug Quality and Security Act in 2013. FDA explains that they register with the agency, are subject to current good manufacturing practice requirements and are inspected on a risk-based schedule. They can supply practitioners without first obtaining an individual patient’s prescription, subject to applicable conditions. FDA’s compounding oversight explanation
A 503B claim is therefore something you can investigate through a facility record. FDA publishes a registered outsourcing-facility table with identifying details and inspection or action information. The table’s update date matters, and some entries indicate that inspection has not yet occurred.
Registration is not approval of every product, an assurance that no action has been taken, or a promise about a prescription’s clinical results. Read the actual entry, rather than treating “FDA-registered” as a general endorsement. If the seller uses a trade name, request the facility’s legal name and location so the lookup matches the right organization.
Who oversees a 503A pharmacy?
State pharmacy boards generally handle day-to-day oversight of state-licensed pharmacies that are not registered outsourcing facilities. FDA nevertheless conducts surveillance and for-cause inspections of such pharmacies and has relevant federal authority. It is inaccurate to translate “503A” into “FDA has no role.” FDA’s oversight explanation
For a practical license check, FDA links to state pharmacy-board resources. Match the name and address carefully. A telehealth platform’s customer-support contact is not necessarily the pharmacy contact, and permission to prescribe through telehealth is a separate matter from the dispensing pharmacy’s licensing.
This guide does not complete an individual license or interstate dispensing check. It explains which record to seek and why a platform’s branding may not be enough to find it.
How the categories affect GLP-1 compounding
FDA’s April 1, 2026 clarification describes restrictions on 503A pharmacies regularly making, or making in inordinate amounts, products essentially copying commercially available drugs. It addresses a prescriber’s documented determination of a significant difference for an identified patient. For 503B facilities, it separately describes bulk-ingredient eligibility through the bulks list or qualifying shortage status. FDA’s GLP-1 clarification
A seller cannot answer a 503B bulk-ingredient question merely by referring to a 503A patient-specific exception. Nor does the presence of a prescription eliminate every copying restriction. These are different conditions, designed for different categories of compounder.
For bulk substances under 503B, FDA specifies the relevant shortage timing at compounding, distribution and dispensing. The agency’s 503B bulk-substance resource is the place to follow the ingredient-list framework. Do not infer a facility’s permission to compound every GLP-1 product simply because its registration appears in FDA’s table.
Does either category make a compounded drug approved?
No. A compounded prescription does not become an FDA-approved drug because its pharmacy is licensed or its facility is registered. FDA explicitly separates compounded drugs from approved generics. Those distinctions are about regulatory status, not an instruction to choose one treatment over another. FDA’s compounded-drug approval explanation
The same care is needed with price comparisons. Our compounded GLP-1 price comparison describes payments and commitments. It does not rank 503A against 503B facilities, certify their practices or establish that a particular prescription meets all conditions.
Questions to ask the service and pharmacy
Ask for the legal names and addresses of the organizations that compound and dispense the product, the category they claim, and the official records supporting that identity. Request a clear product description and a contact who can explain the prescription label. If a platform’s website names several pharmacy partners, ask which one applies to your actual order rather than assuming they all do.
Keep those answers separate from questions about membership fees, shipping and cancellation. Both sets matter when evaluating a telehealth offer, but they establish different things. The provider directory helps you follow services to their published information; pharmacy verification still requires the relevant pharmacy records.
The key distinction is simple: 503A and 503B identify different compounding frameworks, with different prescription, oversight and manufacturing conditions. They are not interchangeable approval labels, and neither resolves every question about a product or seller.